Published by Iain Gilbert on 6th June 2018
(Sharecast News) - Gene and cell therapy group Oxford BioMedica has entered into an exclusive worldwide licensing agreement with Nasdaq-listed Axovant Sciences that will see the pair develop and commercialise OXB-102, a gene therapy for Parkinson's disease developed by the London-listed group.